Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

YMYousef MortazaviNANiran AlmudhfarNKNechama Kalter

Discussion

Loading...

Member takes

Overview

Preclinical development of a novel CAR-T therapy shows enhanced persistence and safety in multiple myeloma, indicating promising clinical potential.

Key Points

  • The research focuses on developing a next-generation BCMA CAR-T therapy to enhance T-cell persistence and reduce toxicities in multiple myeloma.
  • Generated non-viral CRISPR/Cas9-edited BCMA CAR-T cells.
  • Used single-stranded DNA templates for precision in the TRAC locus integration.
  • Conducted cytotoxicity and in vivo efficacy assessments with NSG xenograft models.
  • TRAC-targeted CAR-T showed >99% TCR knockout and high knock-in efficiency up to 72.7%.
  • Demonstrated stronger in vitro anti-myeloma effects than traditional lentiviral CAR-T.
  • Outperformed FDA-approved constructs in tumor clearance and durability of response.

Cite This Study

Mortazavi et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db2ehttps://doi.org/10.1182/blood-2025-5958
View Full Paper
Ask AI
Bookmark
Share